Skip to content

People with HIV in Europe and Australia who switch to injectable treatment with cabotegravir / rilpivirine are just as likely to stay on their new regimen and maintain viral suppression as people taking oral treatment containing dolutegravir or bictegravir, a large international cohort study reported at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2026) last week.

The findings come from one of the largest cohort studies to report on real-world use of the injectable regimen.

Previous cohort studies that reported on real-world use of cabotegravir / rilpivirine were either confined to one clinical centre or country, or lacked a comparator group.

Dr Alisa Timiryasova of the RESPOND HIV Cohort Collaboration looked at real-world outcomes of people who switched to cabotegravir / rilpivirine, comparing them to people who switched to dolutegravir- or bictegravir-based treatment.

The study was designed to measure discontinuation rates and virological and immunological outcomes 6, 12 and 18 months after switching.

The study identified 817 people who switched to cabotegravir / rilpivirine and 5426 who switched to dolutegravir or bictegravir in participating cohorts in Europe and Australia after January 2021. They were followed until the end of August 2024.

Those who switched to cabotegravir / rilpivirine were predominantly male (82%), had a median age of 48 years and were more frequently from southern Europe. They were more likely to be virally suppressed at the time of treatment switch (98%) than people taking dolutegravir or bictegravir (86%). People taking dolutegravir or bictegravir were slightly older (median age 52 years) and a larger proportion were female (28%).

A switch to cabotegravir / rilpivirine was more likely with each year that passed from the beginning of the study in 2021, reflecting greater availability of the combination and familiarity with its use. People in southern Europe were 78% more likely to switch to cabotegravir / rilpivirine than people in western Europe, and people in eastern Europe were 76% less likely to switch to it than people in western Europe.

The analysis measured two outcomes. The first was treatment discontinuation. Rates of treatment discontinuation were comparable: 12% of cabotegravir / rilpivirine switchers and 11% of dolutegravir or bictegravir switchers had discontinued their new regimen after 18 months. There was no difference in the frequency of discontinuation due to treatment failure but people taking cabotegravir / rilpivirine more often discontinued due to adverse events, including injection site reactions (44% vs 27% of discontinuations).

The second outcome, virological and immunological failure, also showed no difference between the two switch regimens. Three per cent of people switching to cabotegravir / rilpivirine and 5% of those switching to dolutegravir or bictegravir had at least one viral load measurement above 200 copies/ml, but just over two-thirds of those with isolated detectable viral load measurements in each group resuppressed viral load without changing treatment.

Among those who needed to change treatment, six out of 22 people in the cabotegravir / rilpivirine group developed treatment-associated resistance mutations during cabotegravir / rilpivirine treatment failure. 

The RESPOND researchers concluded that their findings show that cabotegravir / rilpivirine offers an effective alternative to dolutegravir- or bictegravir-based treatment.

Glossary

HIV

Human immunodeficiency virus, the virus which causes AIDS. There are two variants: HIV-1, and HIV-2. HIV-1 is by far the most common worldwide. See ‘subtype’ for more information.

long-acting

In pharmacology, a medication which maintains its effects over a long period of time, such as an injection or implant.

on

Abbreviation of a Latin term meaning every night.

resistance

A drug-resistant HIV strain is one which is less susceptible to the effects of one or more anti-HIV drugs because of an accumulation of HIV mutations in its genotype. Resistance can be the result of a poor adherence to treatment or of transmission of an already resistant virus.

subtype

In HIV, different strains which can be grouped according to their genes. HIV-1 is classified into three ‘groups,’ M, N, and O. Most HIV-1 is in group M which is further divided into subtypes, A, B, C and D etc. Subtype B is most common in Europe and North America, whilst A, C and D are most important worldwide.

A second European cohort study, COMBINE-2, reported by the NEAT-ID network, reported outcomes in 1022 virally suppressed people who switched to cabotegravir / rilpivirine between December 2020 and September 2025. After a median follow-up of 23 months, 87% were still taking the injectable regimen. Seven participants (0.7%) had experienced virologic failure despite being fully adherent; three developed resistance to cabotegravir and rilpivirine, while three had no resistance mutations. All had resuppressed viral load after switching to alternative regimens.

Other research studies presented at HIV Glasgow 2026 addressed questions about the impact of non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance, and of viral subtype, on cabotegravir / rilpvirine effectiveness in real-world cohorts.

The Spanish RELATIVITY cohort study reported on the impact of NNRTI resistance mutations not associated with rilpivirine resistance on cabotegravir / rilpivirine effectiveness. They identified genotypic resistance reports for 1540 cohort participants; 6% had non-rilpivirine NNRTI resistance mutations, most commonly K103N. Virologic failure and viral blips did not occur at a higher rate in those with non-rilpivirine resistance mutations compared to those without during a median of 26 months of follow-up.

The A6 subtype of HIV raised the risk of virological failure in clinical trials of cabotegravir / rilpivirine but evidence on its real-world impact is limited. The LACRIS cohort study matched 69 people with subtype A6 and 140 people with subtype B who received at least one dose of cabotegravir / rilpivirine. Participants were followed for a median of 19 months, with no difference in discontinuation rates (14% in each group) nor in virologic failure rates (4.5 vs 2 per 100 person-years, p=0.16). Resistance mutations were detectable in all who experienced virologic failure and 80% had resistance to both rilpivirine and cabotegravir. There was no sub-type specific difference in resistance patterns. The LACRIS investigators say that the negative effect of the A6 subtype on responses to cabotegravir / rilpivirine may be less than reported in clinical trials.

 

ConferenceHIV Glasgow 2026
Date8-11 November 2026
LocationGlasgow, UK & online

References

Timiryasova A et al. Treatment uptake and virological and immunological outcomes of cabotegravir+rilpivirine long-acting therapy versus dolutegravir or bictegravir-based regimens in people living with HIV: RESPOND HIV Cohort Collaboration. International Congress on Drug Therapy in HIV Infection, Glasgow, abstract O38.1, 2026.

Pozniak A et al. High virologic suppression and adherence with rare virologic failure in treatment experienced virologically suppressed individuals on cabotegravir+rilpivirine: results from the COMBINE-2 European cohort. International Congress on Drug Therapy in HIV Infection, Glasgow, abstract  P071, 2026.

Rial-Crestelo D et al. Long-term effectiveness of long-acting cabotegravir / rilpivirine in people with HIV harbouring non-rilpivirine NNRTI resistance mutations: 2-Year results from the RELATIVITY cohort. International Congress on Drug Therapy in HIV Infection, Glasgow, abstract O38.2, 2026.

Parczewski M et al. Real-world effectiveness of long-acting cabotegravir and rilpivirine in people with HIV-1 subtype A6: preliminary results from the multinational LACRIS study. International Congress on Drug Therapy in HIV Infection, Glasgow, abstract O44, 2026.

Keith Alcorn

Keith Alcorn

Editorial Consultant

Keith joined the editorial team of the National AIDS Manual (NAM) in 1991, launched the aidsmap website in 1998 and was the Senior Editor of NAM and aidsmap until 2018. He now contributes news and conference reports as a freelancer.

More news

Long-acting injectable treatment superior to daily pills for adolescents in African trial

Dr Mutsa Bwakura Dangarembizi at AIDS 2026. She is talking into a microphone with a screen behind her.

European guidelines widen access to two-drug HIV treatment

Dr Annalisa Marinosci at HIV Glasgow 2026. She is standing behind a lectern.

New antiretrovirals in the pipeline could be part of twice-yearly HIV treatment

Dr Nilay Thakkar (left) and Dr Hyunmoon Back (right) at CROI 2026. They are sitting next to each other with Nilay talking into a microphone.